title: Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of coronary angioplasty.
abstract: To evaluate functional recovery in 20 consecutive patients with acute myocardial infarction who received recombinant tissue-type plasminogen activator, serial two-dimensional echocardiograms were performed before and immediately after tissue plasminogen activator administration and at 1 and 10 days postinfarction. Tissue plasminogen activator was administered intravenously (17 patients) or by intracoronary infusion (3 patients) after angiographic confirmation of total occlusion. Reperfusion, documented by angiography, occurred in 13 of the 20 patients. The mean time from onset of chest pain to thrombolysis was 5.1 +/- 1.1 hours. Echocardiograms were evaluated for regional function with a visual semiquantitative scoring system by two independent observers who had no knowledge of patient identity, temporal sequence, therapy or effect of therapy. There was no immediate or 24 hour improvement in wall motion. At day 10 compared with pretreatment, 28 of 33 reperfused infarct zone segments versus 6 of 20 nonreperfused infarct segments demonstrated improved wall motion (p = 0.01). This improvement did not relate to time from onset of chest pain to successful thrombolysis. Of reperfused infarct zone segments in the distribution of coronary artery balloon dilation, 19 of 23 segments exhibited improvement versus 7 of 17 (reperfused, no angioplasty) and 6 of 20 (nonreperfused, no angioplasty) segments (p = 0.001). Infarct zone segments reperfused at the time of ongoing chest pain demonstrated functional recovery compared with segments reperfused in the absence of chest pain (18 of 23 versus 10 of 20, respectively; p = 0.05). Thus, in this uncontrolled series, there was echocardiographically detectable improvement in function of reperfused infarct segments 10 days after coronary thrombolysis with recombinant tissue plasminogen activator.
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: J L
authors.initials: JL
authors.lastname: Weiss
authors.forename: J A
authors.initials: JA
authors.lastname: Brinker
authors.forename: K P
authors.initials: KP
authors.lastname: Brin
authors.forename: S O
authors.initials: SO
authors.lastname: Gottlieb
authors.forename: L C
authors.initials: LC
authors.lastname: Becker
authors.forename: B H
authors.initials: BH
authors.lastname: Bulkley
authors.forename: N
authors.initials: N
authors.lastname: Chandra
authors.forename: J T
authors.initials: JT
authors.lastname: Flaherty
authors.forename: G
authors.initials: G
authors.lastname: Gerstenblith
mesh_terms: D000328:Adult; D000368:Aged; D000800:Angioplasty, Balloon; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy; D017023:Coronary Angiography; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D004452:Echocardiography; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D009204:Myocardial Revascularization; D010960:Plasminogen Activators / Q000627:therapeutic use*; D012008:Recurrence; D013997:Time Factors
chemical_list: D010960:Plasminogen Activators